BeOne Medicines (NASDAQ:ONC) Insider Titus Ball Sells 169 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Titus Ball sold 169 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $257.20, for a total transaction of $43,466.80. Following the completion of the transaction, the insider directly owned 99,645 shares of the company’s stock, valued at $25,628,694. This represents a 0.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Trading Up 1.4%

ONC stock opened at $268.20 on Tuesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The company has a fifty day moving average price of $298.56 and a two-hundred day moving average price of $314.03. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $239.25 and a one year high of $385.22. The stock has a market cap of $29.43 billion, a price-to-earnings ratio of 60.00 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The firm had revenue of $1.51 billion during the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. Equities analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ONC shares. Jefferies Financial Group cut shares of BeOne Medicines from a “buy” rating to a “hold” rating and dropped their target price for the company from $420.00 to $290.00 in a research report on Monday, March 16th. Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Guggenheim boosted their target price on shares of BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Finally, Truist Financial restated a “buy” rating and issued a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $390.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Mariner LLC lifted its holdings in shares of BeOne Medicines by 3.8% in the fourth quarter. Mariner LLC now owns 883 shares of the company’s stock worth $269,000 after acquiring an additional 32 shares during the last quarter. Signaturefd LLC lifted its holdings in shares of BeOne Medicines by 10.7% in the fourth quarter. Signaturefd LLC now owns 340 shares of the company’s stock worth $103,000 after acquiring an additional 33 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of BeOne Medicines by 21.8% in the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock worth $66,000 after acquiring an additional 39 shares during the last quarter. CWM LLC lifted its holdings in shares of BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares during the last quarter. Finally, Benjamin Edwards Inc. lifted its holdings in shares of BeOne Medicines by 8.0% in the fourth quarter. Benjamin Edwards Inc. now owns 690 shares of the company’s stock worth $210,000 after acquiring an additional 51 shares during the last quarter. Institutional investors own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.